# XenoPort, Inc. clinical trials: 26 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 26 trials with XenoPort, Inc. as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by XenoPort, Inc.: 26 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/xenoport-inc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 26
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 25 newest of 26, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| December 17, 2015 | NCT02633683 | An Extension Study to Evaluate the Efficacy and Safety of HORIZANT in Adolescents With Moderate-to-Severe Primary RLS | XenoPort, Inc. | Phase 4 | Unknown | RLS | 144 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02633683) |
| December 17, 2015 | NCT02633657 | A PK and Safety Evaluation of HORIZANT (Gabapentin Enacarbil) in Adolescents With Moderate-to-Severe Primary RLS | XenoPort, Inc. | Phase 1 | Withdrawn | RLS | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02633657) |
| September 25, 2015 | NCT02560766 | An Efficacy and Safety Evaluation of HORIZANT in Adolescents With Moderate-to-Severe Primary RLS | XenoPort, Inc. | Phase 4 | Unknown | RLS | 132 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02560766) |
| August 20, 2012 | NCT01668667 | Gabapentin Enacarbil (GSK1838262) Adult Restless Leg Syndrome (RLS) Post Marketing Commitment Study | XenoPort, Inc. | Phase 4 | Completed | Restless Legs Syndrome | 501 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01668667) |
| January 24, 2012 | NCT01516372 | A Study to Evaluate the Effect of Gabapentin on Cardiac Repolarization in Healthy Volunteers | XenoPort, Inc. | Phase 1 | Completed | Restless Legs Syndrome | 52 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01516372) |
| November 22, 2011 | NCT01476124 | Drug Drug Interaction Study With Gabapentin Enacarbil and Morphine | XenoPort, Inc. | Phase 1 | Completed | Restless Legs Syndrome | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01476124) |
| August 8, 2011 | NCT01411124 | Study to Assess the Effect of Gabapentin Enacarbil on Simulated Driving in Healthy Subjects | XenoPort, Inc. | Phase 1 | Completed | Restless Legs Syndrome (RLS) | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01411124) |
| May 24, 2011 | NCT01359566 | Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis | XenoPort, Inc. | Phase 3 | Completed | Multiple Sclerosis | 228 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01359566) |
| April 11, 2011 | NCT01332318 | Simulated Driving Study in Restless Legs Syndrome | XenoPort, Inc. | Phase 2 | Completed | Restless Legs Syndrome | 130 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01332318) |
| April 11, 2011 | NCT01332305 | Dose-Response and Pharmacokinetics of Gabapentin Enacarbil (GEn \[XP13512 / GSK1838262\]) in Restless Legs Syndrome | XenoPort, Inc. | Phase 2 | Completed | Restless Legs Syndrome | 217 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01332305) |
| July 28, 2010 | NCT01171313 | A Efficacy, Safety and Pharmacokinetic Study of XP21279 and Sinemet® in Parkinson's Disease Subjects | XenoPort, Inc. | Phase 2 | Completed | Parkinson's Disease | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01171313) |
| September 16, 2009 | NCT00978016 | A Study to Evaluate the Efficacy and Safety of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal... | XenoPort, Inc. | Phase 2 | Completed | Gastroesophageal Reflux Disease | 460 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00978016) |
| June 5, 2009 | NCT00914602 | An Exploratory Study of XP21279 (With Lodosyn®) and Sinemet® in Parkinson's Disease Subjects | XenoPort, Inc. | Phase 1/2 | Completed | Parkinson's Disease | 14 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00914602) |
| February 2, 2009 | NCT00833391 | Relative Bioavailability Study for GSK1838262 (Gabapentin Enacarbil) | XenoPort, Inc. | Phase 1 | Completed | Pharmacokinetics, Healthy Volunteer | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00833391) |
| January 7, 2009 | NCT00817986 | A Study to Evaluate the Safety and Tolerability of Arbaclofen Placarbil (XP19986) in Subjects With Acute Back Spasms | XenoPort, Inc. | Phase 2 | Completed | Back Pain | 161 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00817986) |
| September 8, 2008 | NCT00748098 | Polysomnography Study of GSK1838262 Extended Release Tablets Versus Placebo in RLS and Associated Sleep Disturbance | XenoPort, Inc. | Phase 3 | Completed | Restless Legs Syndrome, Restless Legs Syndrome (RLS) | 136 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00748098) |
| August 27, 2008 | NCT00742209 | Prevention Study in Adult Patients Suffering From Migraine Headaches | XenoPort, Inc. | Phase 2 | Completed | Migraine Disorders, Migraine | 526 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00742209) |
| March 26, 2008 | NCT00643760 | A Study In Patients With Neuropathic Pain From Diabetic Peripheral Neuropathy (DPN) | XenoPort, Inc. | Phase 2 | Completed | Neuropathy, Diabetic | 421 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00643760) |
| February 21, 2008 | NCT00619476 | A Study In Patients With Neuropathic Pain From Post-Herpetic Neuralgia (PHN) | XenoPort, Inc. | Phase 2 | Completed | Neuralgia, Postherpetic | 376 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00619476) |
| February 18, 2008 | NCT00617461 | A Clinical Study in Subjects With Neuropathic Pain From PHN Who Have Had an Inadequate Response to Gabapentin Treatment | XenoPort, Inc. | Phase 2 | Completed | Neuralgia, Postherpetic | 96 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00617461) |
| November 14, 2007 | NCT00557973 | A Safety and Efficacy Study of XP19986 in Subjects With Spasticity Due to Spinal Cord Injury | XenoPort, Inc. | Phase 2 | Completed | Muscle Spasticity | 37 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00557973) |
| November 14, 2007 | NCT00557401 | An Efficacy and Safety Study of XP19986 in Subjects With Symptomatic GERD | XenoPort, Inc. | Phase 2 | Completed | Gastroesophageal Reflux | 156 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00557401) |
| August 17, 2006 | NCT00365352 | XP13512 vs. Placebo in Patients With Restless Legs Syndrome. | XenoPort, Inc. | Phase 3 | Completed | Restless Legs Syndrome | 325 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00365352) |
| June 5, 2006 | NCT00333359 | XP13512 (Gabapentin Enacarbil) Extension Study in Patients With Restless Legs Syndrome. | XenoPort, Inc. | Phase 3 | Completed | Restless Legs Syndrome | 581 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00333359) |
| April 5, 2006 | NCT00311363 | Long-Term Study of Gabapentin Enacarbil (GEn, XP13512) vs. Placebo in Patients With Restless Legs Syndrome. | XenoPort, Inc. | Phase 3 | Completed | Restless Legs Syndrome | 327 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00311363) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 5 |
| Phase 1/2 | 1 |
| Phase 2 | 11 |
| Phase 3 | 6 |
| Phase 4 | 3 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 23 |
| Unknown | 2 |
| Withdrawn | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Restless Legs Syndrome | 14 |
| Neuralgia | 3 |
| Gastroesophageal Reflux | 2 |
| Neuralgia, Postherpetic | 2 |
| Parkinson Disease | 2 |
| Multiple Sclerosis | 1 |
| Diabetic Neuropathies | 1 |
| Muscle Spasticity | 1 |
| Parasomnias | 1 |
| Back Pain | 1 |
| Migraine Disorders | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Waste collection companies in the United States](https://specstream.ai/data/businesses/waste-collection-companies/united-states)
- [Hospices in the United States](https://specstream.ai/data/businesses/hospices/united-states)
- [Web design firms in the United States](https://specstream.ai/data/businesses/web-design-firms/united-states)
- [Hotels in the United States](https://specstream.ai/data/businesses/hotels/united-states)
- [Wholesale florists in the United States](https://specstream.ai/data/businesses/wholesale-florists/united-states)
- [Hydro jetting companies in the United States](https://specstream.ai/data/businesses/hydro-jetting-companies/united-states)
